Tous Actualités
Suivre
Abonner Solianis Monitoring AG

Solianis Monitoring AG

Solianis Monitoring AG on its Way to Success - Market Entry as Planned in 2011

Zurich (ots)

Solianis Monitoring AG presents its Non-Invasive,
Continuous Glucose Monitoring System at the 3rd International 
Conference on Advanced Technologies and Treatments for Diabetes 
(Basel, Switzerland, February 10-13, 2010).
Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis,    
will present the concept of Solianis' proprietary Multisensor     
Glucose Monitoring System (MGMS) which in first tests under daily use
conditions performed according expectations.
"We are pleased with this progress" says Mario Stark, CEO of     
Solianis. "Currently we are setting up manufacturing and will     
subject our final prototype to rigorous clinical tests. These     
tests are the prerequisite to obtain CE approval for market entry in 
Europe in 2011. They will also give us the assurance that our MGMS is
safe and provides people with diabetes with the information they and 
their healthcare professionals need. As an organization, we are 
expanding from a start-up enterprise towards a company which takes 
the responsibility to bring a reliable MGMS to market. Our ongoing 
interaction with scientific and clinical experts as well as patient 
groups ensures that MGMS becomes a system that meets the day-to-day 
needs of people with diabetes, their relatives and healthcare 
professionals".
Solianis Monitoring AG is a Swiss medical device company     
developing an innovative non-invasive Continuous Glucose     
Monitoring (CGM) system for people with diabetes, their relatives and
health care professionals. Its unique and proprietary technology is 
integrated in a Multisensor Glucose Monitoring System (MGMS) which 
continuously delivers information on glucose variations comparable to
the minimally invasive devices currently approved by the FDA.
Solianis was incorporated in May 2005 and has so far been funded  
by private investors, the Pioneer Fond of the Zurich Cantonal     
Bank and the EGS Beteiligungen AG. Solianis plans to introduce     
its first product for insulin dependent patients with diabetes in 
Europe in 2011, after product registration.

Contact:

Micaela Wochner
Tel.: +41/44/306'80'29
Mobile: +41/79/431'79'34
E-Mail: micaela.wochner@solianis.com
Internet: www.solianis.com

Investors:
Mario Stark
Tel.: +41/44/306'80'40
Mobile: +41/79/542'88'74
E-Mail: Mario.stark@solianis.com

Plus de actualités: Solianis Monitoring AG
Plus de actualités: Solianis Monitoring AG